PKU HealthCare

Peking University HealthCare Co., Ltd.
Peking University HealthCare Co., Ltd. (stock abbreviation: PKU HealthCare; stock code: 000788) is a core member enterprise of the healthcare and pharmaceutical industry of Peking University Founder Group — Peking University Healthcare Industry Group. It has more than 50 years of pharmaceutical manufacturing history and possesses a *Technology Center. It is a key backbone enterprise in China's pharmaceutical industry, a national innovative pilot enterprise, a national Torch Program key high-tech enterprise, and an export best-selling brand enterprise strongly supported by Chongqing Municipality.
PKU HealthCare possesses a *Technology Center, with a Synthetic Drug Research Institute, a Formulation Research Institute, and a Health Product Research Institute. It has 58 intermediate and senior R&D personnel, advanced and complete R&D equipment, and a 10,000-square-meter pilot-scale and scale-up testing base. It holds 37 invention patents, has 1 newly applied invention patent, undertakes 3 national key Torch Program projects, and has successfully developed more than 40 new drugs. The company also possesses a modern, international pharmaceutical manufacturing base built according to international high-standard cGMP systems and aligned with international pharmaceutical enterprises, with rich formulation production lines and multi-functional small-scale chemical API pilot production lines. Its products cover nearly 10 major categories including anti-tumor, psychoneurological, cardiovascular, immunosuppressive, anti-microbial, and antipyretic-analgesic categories, with more than one hundred API and formulation varieties.
Relying on the advantageous resources of Peking University Health Science Center and Peking University Healthcare Industry Group, PKU HealthCare focuses on chemical generic drugs, develops oncology chain specialty hospitals, practices the internationalization path, implements the business philosophy of combining pharmaceuticals and healthcare, and is committed to becoming a listed pharmaceutical enterprise with distinctive industry characteristics, unique competitive advantages, leadership in segmented markets, and an important position and influence in China's pharmaceutical industry.